How did ICCC's Q4 earnings surprise impact its annual performance?

ICCC's Q4 earnings surprise had a significant impact on its annual performance, contributing to a robust recovery and positive trends in key financial metrics.

1. **Revenue Growth**: ImmuCell Corporation reported a substantial increase in revenue, with the full year 2024 revenue amounting to US$26.5 million, up by 52% from the previous year. This significant growth reflects the company's successful market expansion and product acceptance.
2. **Narrowing Net Loss**: The net loss for the year 2024 was US$2.16 million, a substantial improvement compared to the US$2.74 million net loss in 2023. This indicates a narrowing of the net loss gap, which is a positive sign for the company's profitability trajectory.
3. **Improved Earnings Per Share (EPS)**: The EPS for 2024 was US$0.26, a marked improvement from the US$0.74 EPS in 2023. This improvement suggests that the company is not only growing its top line but also managing to distribute profits more effectively to its shareholders.
4. **EBITDA Turnaround**: ImmuCell's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) turned positive to $377,000 in Q4, a stark contrast to the negative $1.6 million recorded in the same quarter of the previous year. This turnaround is a strong indicator of improved operational efficiency and cash flow generation.
5. **Sales Growth Momentum**: The company's sales growth has been consistently strong, with an 11% increase in sales reported for the third quarter of 2024. This momentum is likely to have contributed to the annual revenue growth and improved profitability.

In conclusion, ICCC's Q4 earnings surprise had a profound impact on its annual performance, setting the stage for a stronger financial position and a robust recovery in the animal health sector.